| Literature DB >> 35223683 |
Talaat Zakareya1, Mohammad Taha2, Hassan Elzohry1, Ehab Darwiesh3, Reda Aglan1, Mostafa Elhelbawy1, Hazem Zakaria2, Mohamed Deif4, Mohamed Abbasy1.
Abstract
METHODS: 146 adult liver transplant recipients were included. Univariate and multivariate analyses were used to determine the independent predictors of survival at 3 months, 1 year, and 5 years. The receiver operating characteristic (ROC) curve for the BAR score was plotted, and the area under the ROC curve (AUROC) was calculated. Kaplan-Meier curve and log-rank test were used to compare survival above and below the best cutoff values.Entities:
Mesh:
Year: 2022 PMID: 35223683 PMCID: PMC8881181 DOI: 10.1155/2022/2877859
Source DB: PubMed Journal: Can J Gastroenterol Hepatol ISSN: 2291-2789
Demographic, clinical, laboratory, operative, and survival data.
|
| Mean ± SD, |
|
| |
| Demographics | |
| Age (years) | 52.45 |
| Sex | |
| Males | 87 (59.6) |
| Females | 59 (40.4) |
| Etiology of liver disease | |
| HCV | 125 (85.6) |
| HBV | 6 (4.1) |
| Combined HCV and HBV | 3 (2) |
| NAFLD | 5 (3.4) |
| AIH | 3 (2) |
| Others | 4 (2.7) |
| Clinical data | |
| BMI (kg/m2) | 25.47 ± 3.18 |
| Preexisting DM | 31 (21.2) |
| Preexisting HT | 9 (6.2) |
| Life support | 20 (13.7) |
| ICU stay | 9.79 ± 3.40 |
| Total hospital stay | 24.79 ± 5.65 |
| HCC | 37 (25.3) |
| Laboratory data and scores | |
| Albumin (gm/dL) | 2.58 ± 0.78 |
| Bilirubin (mg/dL) | 3.67 ± 5.51 |
| INR | 1.40 ± 0.30 |
| Creatinine (mg/dL) | 0.98 ± 0.26 |
| AST (IU/L) | 66.37 ± 17.50 |
| ALT (IU/L) | 40.96 ± 10.79 |
| Hb (gm/dL) | 11.06 ± 1.13 |
| WBC (×10³/mm³) | 5.00 ± 1.45 |
| Platelets (×10³/mm³) | 172.87 ± 127.85 |
| MELD score | 14.45 ± 5.0 |
| BAR score | 7.58 ± 3.83 |
| Donor age (years) | 26.45 ± 6.06 |
| Operative data | |
| Graft weight (gm) | 870.0 ± 15.0 |
| GRWR | 1.05 ± 0.15 |
| CIT (minutes) | 61.81 ± 25.49 |
| WIT (minutes) | 53.01 ± 16.20 |
| TOT (hours) | 13.88 ± 3.00 |
| Blood transfusion (units) | 5.17 ± 4.64 |
| Survival data | |
| Three-month survival | 130 (89) |
| One-year survival | 115 (78.8) |
| Five-year survival | 105 (72) |
BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Hb, hemoglobin; WBC, white blood count; HCV, hepatitis C virus; INR, international normalized ratio.
Figure 1Receiver operating characteristic curve for the BAR score in predicting post-transplant 3-month survival. BAR, balance of risk; AUROC, area under the receiver operating characteristic curve.
Univariate and multivariate analysis of variables associated with survival after LDLT.
| Variables | 3-month survival analysis | 1-year survival analysis | 5-year survival analysis | ||||||||||||
| Survival | Univariate analysis | Cox regression model | Survival | Univariate analysis | Cox regression model | Survival | Univariate analysis | Cox regression model | |||||||
| Yes/no 130/16 |
| OR | CI (95%) |
| Yes/no 115/31 |
| OR | CI (95%) |
| Yes/no 105/41 |
| OR | CI (95%) |
| |
|
| |||||||||||||||
| Sex | |||||||||||||||
| Males | 78/9 | 0.291 | 69/19 | 0.703 | 63/24 | 0.952 | |||||||||
| Females | 52/7 | 46/12 | 42/17 | ||||||||||||
| HCC | |||||||||||||||
| No | 101/8 | 0.540 | 92/17 | 0.815 | 93/16 | 0.720 | |||||||||
| Yes | 29/8 | 23/14 | 12/25 | ||||||||||||
| WIT | |||||||||||||||
| < 45 min | 46/4 | 0.944 | 37/9 | 0.627 | 31/15 | 0.132 | |||||||||
| ≥ 45 min | 84/12 | 78/22 | 74/26 | ||||||||||||
| GRWR | |||||||||||||||
| 0.8–1 | 68/12 | 0.888 | 64/16 | 0.776 | 60/20 | 0.773 | |||||||||
| > 1.0 | 62/4 | 51/15 | 45/21 | ||||||||||||
| TOT | |||||||||||||||
| < 12 hour | 82/4 | 0.001 | 7.34 | 2.06–26.23 | 0.002 | 75/11 | 0.008∗ | 3.37 | 1.6–7.2 | 0.004 | 69/17 | 0.009∗ | 2.66 | 1.42–5.0 | 0.056 |
| ≥ 12 hour | 48/12 | 40/20 | 36/24 | ||||||||||||
| Blood transfusion | |||||||||||||||
| < 6 units | 116/5 | 0.040 | 1.31 | 0.47–3.65 | 0.601 | 102/19 | 0.559 | 93/28 | 0.284 | ||||||
| ≥ 6 units | 14/11 | 13/12 | 12/13 | ||||||||||||
| ICU stay | |||||||||||||||
| < 10 days | 74/7 | 0.046 | 1.12 | 0.32–3.98 | 0.860 | 61/15 | 0.156 | 60/21 | 0.349 | ||||||
| ≥ 10 days | 56/9 | 54/16 | 45/20 | ||||||||||||
| Total hospital stay | |||||||||||||||
| < 1 month | 103/15 | 0.327 | 27/6 | 0.719 | 84/34 | 0.864 | |||||||||
| ≥ 1 month | 27/1 | 119/10 | 19/7 | ||||||||||||
| BAR score | |||||||||||||||
| < 10 | 115/8 | <0.0001 | 6.35 | 2.28–17.68 | <0.0001 | 101/22 | 0.001∗ | 3.21 | 1.46–7.08 | 0.001 | 93/30 | 0.002∗ | 2.83 | 1.40–5.7 | 0.044 |
| ≥ 10 | 15/8 | 14/9 | 12/11 | ||||||||||||
HCC, hepatocellular carcinoma; WIT, warm ischemia time; GRWR, graft recipient weight ratio; TOT, total operative time; ICU, intensive care unit; BAR, balance of risk; ∗indicates statistically significant value.
Figure 2Receiver operating characteristic curve for the BAR score in predicting post-transplant 1-year survival. BAR, balance of risk; AUROC, area under the receiver operating characteristic curve.
Figure 3Receiver operating characteristic curve for the BAR score in predicting post-transplant 5-year survival. BAR, balance of risk; AUROC, area under the receiver operating characteristic curve.
Figure 4Post-transplant 3-month survival (Kaplan–Meier curve with log-rank test) for patients with the BAR score < and ≥10 points. BAR, balance of risk.
Figure 5Post-transplant cumulative 1-year survival (Kaplan–Meier curve with log-rank test) for patients with the BAR score < and ≥10 points. BAR, balance of risk.
Figure 6Post-transplant cumulative 5-year survival (Kaplan–Meier curve with log-rank test) for patients with the BAR score < and ≥10 points. BAR, balance of risk.